Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

63.36USD
22 Sep 2017
Change (% chg)

$0.03 (+0.05%)
Prev Close
$63.33
Open
$63.33
Day's High
$63.53
Day's Low
$63.05
Volume
1,116,434
Avg. Vol
1,823,434
52-wk High
$63.74
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Japanese ministry of Health, Labor and Welfare approves Opdivo for treatment of unresectable advanced or recurrent gastric cancer
Friday, 22 Sep 2017 05:00am EDT 

Sept 22 (Reuters) - Bristol-Myers Squibb Co - :Bristol-Myers Squibb - Japanese Ministry of Health, Labor and Welfare has approved Opdivo for treatment of unresectable advanced or recurrent gastric cancer.  Full Article

Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201
Monday, 28 Aug 2017 04:01pm EDT 

Aug 28 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Bristol-Myers Squibb and Daiichi Sankyo announce research collaboration to evaluate Opdivo (Nivolumab) and DS-8201 in HER2-expressing breast and bladder cancers.Bristol-Myers Squibb Co - ‍Study is expected to begin enrollment in Q1 of 2018 in US and Europe​.Bristol-Myers Squibb Co - ‍Under terms of agreement, Daiichi Sankyo will be sponsor conducting trial​.  Full Article

Bristol-Myers Squibb announces topline results
Tuesday, 15 Aug 2017 04:30pm EDT 

Aug 15 (Reuters) - Bristol-myers Squibb Co ::Bristol-Myers Squibb announces topline results from checkmate -214, a phase 3 study of opdivo in combination with yervoy in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.Bristol-Myers Squibb Co - ‍co-primary endpoint of objective response rate was met for combination of opdivo and yervoy​.Bristol-Myers Squibb Co - ‍study will continue as planned to allow third co-primary endpoint of overall survival to mature​.Bristol-Myers - ‍tolerability profile observed in checkmate-214 consistent with that observed in previously reported studies of the dosing schedule​.Bristol-Myers Squibb- ‍co-primary endpoint of progression-free survival favored combination of opdivo, yervoy versus. Sunitinib but didn't reach statistical significance​.  Full Article

Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study
Friday, 2 Jun 2017 06:59am EDT 

June 2 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers - Announces first disclosure of data from a cohort of phase 1/2 CheckMate -358 study.Bristol-Myers Squibb Co says median duration of response has not been reached after 6 months of follow-up.Bristol-Myers Squibb Co - Grade 3/4 treatment-related adverse events occurred in 12.5% of patients in phase 1/2 checkmate -358 study evaluating Opdivo.Bristol-Myers - Opdivo showed safety profile consistent with previous results seen with Opdivo monotherapy in other tumor types, in CheckMate -358​ study.Bristol-Myers - ‍overall response rate of 26.3% in patients with cervical cancer regardless of PD-l1, HPV status and number of prior systemic therapies​.  Full Article

Bristol-Myers Squibb posts Q1 earnings per share of $0.94
Thursday, 27 Apr 2017 06:59am EDT 

April 27 (Reuters) - Bristol-myers Squibb ::Q1 earnings per share $0.94; Q1 adjusted earnings per share $0.84; Q1 revenues $4.93 billion, up 12 percent.Increasing 2017 earnings per share guidance range to $2.72 - $2.87 from $2.47 - $2.67.Sees 2017 worldwide revenues increasing in the mid-single digits.Increasing 2017 non-gaap earnings per share guidance range to $2.85 - $3.00 from $2.70 - $2.90.Q1 Opdivo worldwide revenues $1.13 billion, up 60 percent.Sees 2017 research and development expenses increasing in high-teens digit range for gaap and increasing in low-double digits range for non-GAAP.Q1 Sprycel worldwide revenues $463 million, up 14 percent.Q1 Yervoy worldwide revenues $330 million, up 25 percent.Q1 Eliquis worldwide revenues $1.10 billion, up 50 percent.  Full Article

Jana Partners takes sole share stake in Bristol-Myers, Cognizant
Tuesday, 14 Feb 2017 03:51pm EST 

Jana Partners LLC : Jana Partners LLC takes sole share stake of 3.9 million shares in Bristol-Myers - SEC filing . Jana Partners LLC takes sole share stake in Cognizant Technology Solutions . Jana Partners LLC takes sole share stake of 3.2 million shares in Salesforce.com Inc . Jana Partners LLC dissolves sole share stake in US Foods Holding Corp . Jana Partners LLC dissolves sole share stake in Graphic Packaging Holding Co .Jana Partners LLC - Change in holdings are as of Dec 31, 2016 and compared with the previous quarter ended as of Sept 30, 2016.  Full Article

Bristol-Myers Squibb Canada reached an agreement with Pan-Canadian Pharmaceutical Alliance
Friday, 10 Feb 2017 08:00am EST 

Bristol-myers Squibb Co : Bristol-Myers squibb canada - reached an agreement with pan-canadian pharmaceutical alliance (pcpa) for immuno-oncology treatment opdivo .Bristol-Myers squibb canada - will work with provincial, federal, territorial jurisdiction to implement agreement to make opdivo accessible.  Full Article

CytomX says clinical candidate probody from Bristol-Myers Squibb collaboration selected
Tuesday, 13 Dec 2016 08:00am EST 

CytomX Therapeutics Inc : CytomX announces selection by Bristol-Myers Squibb of first clinical candidate probody from collaboration . Upon selection of third and fourth targets, Bristol-Myers Squibb paid CytomX selection payments .Achieving this milestone results in a $2 million payment to CytomX.  Full Article

Bristol-Myers receives positive CHMP opinion for Opdivo
Friday, 14 Oct 2016 06:59am EDT 

Bristol-Myers Squibb Co : Receives positive CHMP opinion for Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with Brentuximab Vedot . Says CHMP decision based on overall response rate demonstrated by data from two trials, Checkmate -205 and Checkmate -039 .CHMP recommendation will now be reviewed by European commission.  Full Article

U.S. FDA warns about the risk of Hepatitis B
Tuesday, 4 Oct 2016 05:31pm EDT 

: U.S. FDA warns about the risk of Hepatitis B reactivating in some patients treated with direct-acting antivirals for Hepatitis C .Requiring a boxed warning about risk of HBV reactivation to be added to drug labels of direct-acting antiviral medicines for Hepatitis C virus.  Full Article

BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

* AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors